JP7227003B2 - ウロリチン化合物を含む組成物 - Google Patents

ウロリチン化合物を含む組成物 Download PDF

Info

Publication number
JP7227003B2
JP7227003B2 JP2018529732A JP2018529732A JP7227003B2 JP 7227003 B2 JP7227003 B2 JP 7227003B2 JP 2018529732 A JP2018529732 A JP 2018529732A JP 2018529732 A JP2018529732 A JP 2018529732A JP 7227003 B2 JP7227003 B2 JP 7227003B2
Authority
JP
Japan
Prior art keywords
composition
weight
muscle
composition according
urolithin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018529732A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018533618A5 (enExample
JP2018533618A (ja
Inventor
アンドリュー，ペネロペ
リンシュ，クリストファー
ブランコ－ボーズ，ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amazentis SA
Original Assignee
Amazentis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amazentis SA filed Critical Amazentis SA
Publication of JP2018533618A publication Critical patent/JP2018533618A/ja
Publication of JP2018533618A5 publication Critical patent/JP2018533618A5/ja
Priority to JP2022144671A priority Critical patent/JP2022177130A/ja
Application granted granted Critical
Publication of JP7227003B2 publication Critical patent/JP7227003B2/ja
Priority to JP2024174863A priority patent/JP2025004129A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018529732A 2015-08-28 2016-08-26 ウロリチン化合物を含む組成物 Active JP7227003B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022144671A JP2022177130A (ja) 2015-08-28 2022-09-12 ウロリチン化合物を含む組成物
JP2024174863A JP2025004129A (ja) 2015-08-28 2024-10-04 ウロリチン化合物を含む組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1515387.7 2015-08-28
GBGB1515387.7A GB201515387D0 (en) 2015-08-28 2015-08-28 Compositions
PCT/EP2016/070255 WO2017036992A1 (en) 2015-08-28 2016-08-26 Compositions comprising urolithin compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022144671A Division JP2022177130A (ja) 2015-08-28 2022-09-12 ウロリチン化合物を含む組成物

Publications (3)

Publication Number Publication Date
JP2018533618A JP2018533618A (ja) 2018-11-15
JP2018533618A5 JP2018533618A5 (enExample) 2019-10-03
JP7227003B2 true JP7227003B2 (ja) 2023-02-21

Family

ID=54326542

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018529732A Active JP7227003B2 (ja) 2015-08-28 2016-08-26 ウロリチン化合物を含む組成物
JP2022144671A Pending JP2022177130A (ja) 2015-08-28 2022-09-12 ウロリチン化合物を含む組成物
JP2024174863A Pending JP2025004129A (ja) 2015-08-28 2024-10-04 ウロリチン化合物を含む組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022144671A Pending JP2022177130A (ja) 2015-08-28 2022-09-12 ウロリチン化合物を含む組成物
JP2024174863A Pending JP2025004129A (ja) 2015-08-28 2024-10-04 ウロリチン化合物を含む組成物

Country Status (15)

Country Link
US (4) US10695320B2 (enExample)
EP (1) EP3340977B1 (enExample)
JP (3) JP7227003B2 (enExample)
KR (2) KR102822365B1 (enExample)
CN (1) CN108289879A (enExample)
AU (1) AU2016314987B2 (enExample)
BR (1) BR112018003745B1 (enExample)
CA (1) CA2996724C (enExample)
ES (1) ES2936723T3 (enExample)
GB (1) GB201515387D0 (enExample)
MX (1) MX2018002543A (enExample)
PT (1) PT3340977T (enExample)
RU (1) RU2754761C2 (enExample)
SG (1) SG10202001793PA (enExample)
WO (1) WO2017036992A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025004129A (ja) * 2015-08-28 2025-01-14 アマゼンティス エスアー ウロリチン化合物を含む組成物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018162650A1 (en) * 2017-03-08 2018-09-13 Amazentis Sa Methods for improving mitophagy in subjects
US20210267932A1 (en) 2018-05-15 2021-09-02 University Of Louisville Research Foundation, Inc. Compounds, compositions, methods of using, and methods for preparing compounds
GB201916046D0 (en) * 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
CA3188397A1 (en) 2020-09-25 2022-03-31 Anupama Dattatreya Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
JP7541673B2 (ja) * 2020-11-30 2024-08-29 国立研究開発法人産業技術総合研究所 筋ジストロフィーの抗炎症剤、筋ジストロフィーにおける抗炎症のための中心静脈栄養用組成物および筋ジストロフィーの抗炎症用食品組成物
KR102623664B1 (ko) 2020-12-10 2024-01-12 서울대학교산학협력단 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법
CN117015530A (zh) 2021-01-27 2023-11-07 范徳利亚股份公司 尿石素衍生物及其使用方法
EP4085906A1 (en) * 2021-05-06 2022-11-09 Universite De Bordeaux Composition comprising ppar-modulator and an urolithin derivative and uses thereof
CN113813255B (zh) * 2021-10-20 2023-09-01 山东大学 尿石素a及其衍生物在肿瘤免疫治疗的应用
WO2023199908A1 (ja) * 2022-04-11 2023-10-19 株式会社ダイセル 乳化組成物の製造方法
GB202219317D0 (en) * 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
EP4642448A1 (en) * 2022-12-27 2025-11-05 Indian Institute of Science A method for the treatment of epilepsy
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
EP4555997A1 (en) * 2023-11-15 2025-05-21 Science4Beauty Sp. z o.o. Water-soluble composition comprising urolithin
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use
KR20250158913A (ko) 2024-04-30 2025-11-07 주식회사 파이안바이오테크놀로지 유로리틴을 함유하는 탈모완화제와 모발성장촉진제
WO2025252771A1 (en) 2024-06-03 2025-12-11 Amazentis Sa Urolithin combinations

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006035900A1 (ja) 2004-09-29 2006-04-06 San-Ei Gen F.F.I., Inc. コエンザイムｑ１０含有乳化組成物
JP2008503456A (ja) 2004-06-18 2008-02-07 ナトレオン，インコーポレイテッド ドコサヘキサエン酸（ｄｈａ）及びエイコサペンタエン酸（ｅｐａ）の安定した生理活性代謝産物の組成物
JP2012502973A (ja) 2008-09-17 2012-02-02 キアズマ インコーポレイテッド 医薬組成物および関連する送達方法
JP2012067115A (ja) 1999-02-22 2012-04-05 Merrion Research Iii Ltd 促進剤を含む固体経口剤形
JP2012111712A (ja) 2010-11-25 2012-06-14 Toyo Capsule Kk 油性ビタミンｃ経口投与用組成物
JP2013518127A (ja) 2010-01-28 2013-05-20 メリオン・リサーチ・Ｉｉｉ・リミテッド 増強剤を含む固形医薬組成物およびその調製方法
JP2013522028A (ja) 2010-03-22 2013-06-13 エムジェイアール ファームジェット ゲーエムベーハー 微小粒子またはナノ粒子を生成する方法および装置
JP2013525337A (ja) 2010-04-20 2013-06-20 シプラ・リミテッド 医薬組成物
JP2013166797A (ja) 1996-03-26 2013-08-29 Eli Lilly & Co ベンゾチオフェン類、それを含む製剤、および方法
JP2013544829A (ja) 2010-11-24 2013-12-19 エクセリクシス， インク． ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピンおよびその使用と製造方法
JP2014501764A (ja) 2010-12-23 2014-01-23 アマゼンティス エスアー ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド 経口投与用の鉄の医薬組成物
JP2015098489A (ja) 2010-03-19 2015-05-28 ボストン バイオメディカル， インコーポレイテッド がん幹細胞を標的とするための新規の化合物および組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3786447B2 (ja) * 1995-03-31 2006-06-14 エーザイ株式会社 Ｃ型肝炎の予防・治療剤
WO1999053941A1 (fr) * 1998-04-15 1999-10-28 Shionogi & Co., Ltd. Preparations orales contenant des derives de trh
US6623734B2 (en) * 2000-06-22 2003-09-23 Soft Gel Technologies, Inc. Super absorption coenzyme Q10
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
EP2145904A1 (de) 2008-07-18 2010-01-20 Basf Se Verfahren zur enzymkatalysierten Hydrolyse von Polyacrylsäureestern sowie dafür zu verwendende Esterasen
CA2826884A1 (en) * 2012-09-14 2014-03-14 Natreon, Inc. Method for improving endothelial function and decreasing cardiovascular morbidity using shilajit
GB201323008D0 (en) * 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201515391D0 (en) * 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013166797A (ja) 1996-03-26 2013-08-29 Eli Lilly & Co ベンゾチオフェン類、それを含む製剤、および方法
JP2012067115A (ja) 1999-02-22 2012-04-05 Merrion Research Iii Ltd 促進剤を含む固体経口剤形
JP2008503456A (ja) 2004-06-18 2008-02-07 ナトレオン，インコーポレイテッド ドコサヘキサエン酸（ｄｈａ）及びエイコサペンタエン酸（ｅｐａ）の安定した生理活性代謝産物の組成物
WO2006035900A1 (ja) 2004-09-29 2006-04-06 San-Ei Gen F.F.I., Inc. コエンザイムｑ１０含有乳化組成物
JP2012502973A (ja) 2008-09-17 2012-02-02 キアズマ インコーポレイテッド 医薬組成物および関連する送達方法
JP2013518127A (ja) 2010-01-28 2013-05-20 メリオン・リサーチ・Ｉｉｉ・リミテッド 増強剤を含む固形医薬組成物およびその調製方法
JP2015098489A (ja) 2010-03-19 2015-05-28 ボストン バイオメディカル， インコーポレイテッド がん幹細胞を標的とするための新規の化合物および組成物
JP2013522028A (ja) 2010-03-22 2013-06-13 エムジェイアール ファームジェット ゲーエムベーハー 微小粒子またはナノ粒子を生成する方法および装置
JP2013525337A (ja) 2010-04-20 2013-06-20 シプラ・リミテッド 医薬組成物
JP2013544829A (ja) 2010-11-24 2013-12-19 エクセリクシス， インク． ＰＩ３Ｋ／ｍＴＯＲの阻害剤としてのベンゾオキサゼピンおよびその使用と製造方法
JP2012111712A (ja) 2010-11-25 2012-06-14 Toyo Capsule Kk 油性ビタミンｃ経口投与用組成物
JP2014501764A (ja) 2010-12-23 2014-01-23 アマゼンティス エスアー ミトコンドリア機能向上と、神経変性疾患および認知障害治療とのための組成物および方法
JP2014501784A (ja) 2011-01-07 2014-01-23 メリオン・リサーチ・Ｉｉｉ・リミテッド 経口投与用の鉄の医薬組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
第１節 吸収促進剤 ２．膜透過バリヤー，経口投与製剤の設計と評価，1995年，第198-212頁

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025004129A (ja) * 2015-08-28 2025-01-14 アマゼンティス エスアー ウロリチン化合物を含む組成物

Also Published As

Publication number Publication date
AU2016314987A1 (en) 2018-03-29
CN108289879A (zh) 2018-07-17
KR20240060826A (ko) 2024-05-08
WO2017036992A1 (en) 2017-03-09
KR102822365B1 (ko) 2025-06-17
KR20180037052A (ko) 2018-04-10
JP2022177130A (ja) 2022-11-30
AU2016314987B2 (en) 2021-07-08
PT3340977T (pt) 2023-01-31
HK1257500A1 (en) 2019-10-25
US11925616B2 (en) 2024-03-12
US20200323818A1 (en) 2020-10-15
RU2754761C2 (ru) 2021-09-07
US11337957B2 (en) 2022-05-24
RU2018108136A (ru) 2019-09-30
EP3340977A1 (en) 2018-07-04
JP2025004129A (ja) 2025-01-14
CA2996724A1 (en) 2017-03-09
ES2936723T3 (es) 2023-03-21
US20180243261A1 (en) 2018-08-30
US10695320B2 (en) 2020-06-30
US20240148690A1 (en) 2024-05-09
BR112018003745B1 (pt) 2023-11-07
KR102660005B1 (ko) 2024-04-22
MX2018002543A (es) 2018-06-15
US20220323407A1 (en) 2022-10-13
GB201515387D0 (en) 2015-10-14
JP2018533618A (ja) 2018-11-15
EP3340977B1 (en) 2022-11-02
CA2996724C (en) 2024-05-21
SG10202001793PA (en) 2020-04-29
BR112018003745A2 (pt) 2018-09-25
RU2018108136A3 (enExample) 2020-01-31

Similar Documents

Publication Publication Date Title
US11925616B2 (en) Compositions comprising urolithin compounds
JP2023100869A (ja) 対象におけるマイトファジーを改善するための方法
JP7161402B2 (ja) ウロリチン化合物を含む組成物
JP2023100870A (ja) 対象におけるマイトファジーを改善するための方法
JP2699083B2 (ja) リチウム塩含有薬学的組成物
JP2019182881A (ja) 末梢神経障害の予防又は改善用組成物
HK1257500B (en) Compositions comprising urolithin compounds
KR20250133322A (ko) 우롤리틴과 케톤체의 조합물
BR112019012741A2 (pt) composição, formulação, método para prevenir e/ou tratar caquexia em um indivíduo, uso da composição, e, produto de uso médico especial, produto de alimentos para uso específico de saúde, produto para alimentos para fins médicos especiais, produto de alimento para uso dietético especial, produto de nutrição médica e produto de alimento médico.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190826

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200708

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210609

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220912

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220928

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221104

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230209

R150 Certificate of patent or registration of utility model

Ref document number: 7227003

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150